Biomimetic drug-delivery systems for the management of brain diseases

Chen, Yao-Xing; Wei, Chenxuan; Lyu, Ying-Qi; Chen, Hongzhuan; Jiang, Gan; Gao, Xiaoling

doi:10.1039/c9bm01395d

Cited by 61 publications

(55 citation statements)

References 163 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For brain diseases therapy, a minimal effective concentration of drug at the lesion spot is required for exerting desirable therapeutic effect. Drugs usually lack targeting effect, but drug delivery systems, especially biomimetic vehicles can alter the drug biodistribution and target the lesion spot by the endogenous driving force or intrinsic binding properties, such as cell-based vehicles or peptide ligands modified vehicles (Chen et al, 2020). Targets of diseased cells may be different, the discrimination ability of delivery systems to normal cells and diseased cells requires the understanding of the pathophysiology of the brain disease.…”

Section: Targeting Lesion Spotsmentioning

confidence: 99%

“…Drugs are usually cleared quickly from circulation. The fate of drugs or nanoparticles is hard to predict after phagocytosis, clearance, degeneration, or protein corona formation (Barbero et al., 2017 ; Chinen et al., 2017 ; Fromen et al., 2017 ). Also, degradation products may cause unwanted toxicity, thus limiting potential clinical applications.…”

Section: Challenges Of Brain Drug Deliverymentioning

confidence: 99%

“…In recent years, emerging efforts have been dedicated to developing biomimetic drug À delivery systems by using complex natural biological components or mimicking the structure (Parodi et al, 2013;Hu et al, 2015;Fang et al, 2018). For delivery of drugs for brain diseases therapy, biomimetic drug delivery systems may help increase biocompatibility, long À term circulation and more importantly, penetrate the BBB to increase drug concentration at the target site (Chen et al, 2020). The most commonly developed cell-based vehicles for biomimetic drug delivery include living cells (Wang et al, 2015), cell membranes (Luk & Zhang, 2015), and nanovesicles (Usman et al, 2018), depending on the target of disease and cargo for delivery.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

From blood to brain: blood cell-based biomimetic drug delivery systems

Liu

et al. 2021

Drug Delivery

View full text Add to dashboard Cite

Brain drug delivery remains a major difficulty for several challenges including the blood-brain barrier, lesion spot targeting, and stability during circulation. Blood cells including erythrocytes, platelets, and various subpopulations of leukocytes have distinct features such as long-circulation, natural targeting, and chemotaxis. The development of biomimetic drug delivery systems based on blood cells for brain drug delivery is growing fast by using living cells, membrane coating nanotechnology, or cell membrane-derived nanovesicles. Blood cell-based vehicles are superior delivery systems for their engineering feasibility and versatile delivery ability of chemicals, proteins, and all kinds of nanoparticles. Here, we focus on advances of blood cell-based biomimetic carriers for from blood to brain drug delivery and discuss their translational challenges in the future.

show abstract

Section: Targeting Lesion Spotsmentioning

confidence: 99%

Section: Challenges Of Brain Drug Deliverymentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

From blood to brain: blood cell-based biomimetic drug delivery systems

Liu

et al. 2021

Drug Delivery

View full text Add to dashboard Cite

show abstract

“…These PMVs loaded with natural compound and magnetic NPs can reach the stroke-induced damaged sites faster and more active when external magnetic fields are applied near the damaged sites, because of the magnetic guidance effect. Thus, biomimetic exosomes can be promising nanocarriers exhibiting specific neuroinflammation-targeting delivery with the application of external magnetic field or HIFU or extra surface functionalization [ 249 , 250 ].…”

Section: Various Nanocarriers Containing Natural Compounds For Thementioning

confidence: 99%

The Role of Natural Compounds and their Nanocarriers in the Treatment of CNS Inflammation

et al. 2020

View full text Add to dashboard Cite

Neuroinflammation, which is involved in various inflammatory cascades in nervous tissues, can result in persistent and chronic apoptotic neuronal cell death and programmed cell death, triggering various degenerative disorders of the central nervous system (CNS). The neuroprotective effects of natural compounds against neuroinflammation are mainly mediated by their antioxidant, anti-inflammatory, and antiapoptotic properties that specifically promote or inhibit various molecular signal transduction pathways. However, natural compounds have several limitations, such as their pharmacokinetic properties and stability, which hinder their clinical development and use as medicines. This review discusses the molecular mechanisms of neuroinflammation and degenerative diseases of CNS. In addition, it emphasizes potential natural compounds and their promising nanocarriers for overcoming their limitations in the treatment of neuroinflammation. Moreover, recent promising CNS inflammation-targeted nanocarrier systems implementing lesion site-specific active targeting strategies for CNS inflammation are also discussed.

show abstract

“…In recent years, researchers have attempted to construct biomimetic drug-delivery systems (BDDSs) that were combined with nanoparticles and biomimetic materials. This causes drug nanoparticles to become self-recognizing substances that avoid recognition by the immune system [ 16 , 17 ]. Among the many biomimetic materials, the cell membrane is one of the materials that endows nanoparticles with unique biological properties [ 18 ].…”

Section: Introductionmentioning

confidence: 99%

Cancer Cell Membrane-Coated Nanosuspensions for Enhanced Chemotherapeutic Treatment of Glioma

Fan

Hao²,

Cui³

et al. 2021

Molecules

View full text Add to dashboard Cite

Effective intracerebral delivery is key for glioma treatment. However, the drug delivery system within the brain is largely limited by its own adverse physical and chemical properties, low targeting efficiency, the blood–brain barrier and the blood–brain tumor barrier. Herein, we developed a simple, safe and efficient biomimetic nanosuspension. The C6 cell membrane (CCM) was utilized to camouflaged the 10-hydroxycamptothecin nanosuspension (HCPT-NS) in order to obtain HCPT-NS/CCM. Through the use of immune escape and homotypic binding of the cancer cell membrane, HCPT-NS/CCM was able to penetrate the blood–brain barrier and target tumors. The HCPT-NS is only comprised of drugs, as well as a small amount of stabilizers that are characterized by a simple preparation method and high drug loading. Similarly, the HCPT-NS/CCM is able to achieve targeted treatment of glioma without any ligand modification, which leads it to be stable and efficient. Cellular uptake and in vivo imaging experiments demonstrated that HCPT-NS/CCM is able to effectively cross the blood–brain barrier and was concentrated at the glioma site due to the natural homing pathway. Our results reveal that the glioma cancer cell membrane is able to promote drug transport into the brain and enter the tumor via a homologous targeting mechanism.

show abstract

Biomimetic drug-delivery systems for the management of brain diseases

Abstract: This review summarizes the biological properties of biomimetic DDSs and their applications in the treatment of CNS diseases.

Cited by 61 publications

References 163 publications

From blood to brain: blood cell-based biomimetic drug delivery systems

From blood to brain: blood cell-based biomimetic drug delivery systems

The Role of Natural Compounds and their Nanocarriers in the Treatment of CNS Inflammation

Cancer Cell Membrane-Coated Nanosuspensions for Enhanced Chemotherapeutic Treatment of Glioma

Contact Info

Product

Resources

About